This is a working overview of dual agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-22 and is reviewed periodically as new material appears.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized peptide powder form |
| Solubility | Soluble in aqueous buffer | Dissolves in water and buffered saline |
| Typical storage temperature | 2 to 8 degrees Celsius | Refrigerated; protect from freezing and light |
| Common analytical method | Reversed-phase HPLC | Purity and related substances |
| Mass confirmation | Electrospray mass spectrometry | Verifies approximately 4,813 Da |
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
After passing the OBBBA, Congress needed to approve a new spending bill to fund the federal government beyond October 1, 2025, when the previous budget expired. The 53 Republican senators had to either eliminate the filibuster or convince at least seven Democrats to join them in order to reach the 60-vote supermajority required to advance their proposal. Most Democrats opposed the Republican plan and requested a compromise that would extend the healthcare subsidies cut by the OBBBA. The resulting stalemate triggered the 2025 United States federal government shutdown, which became the longest government shutdown in U.S. history.
Concurrently, the Bureau of Longitude Studies and the Observatory were undertaking a comprehensive review of his extensive barometric and astronomical measurements. Furthermore, artists had been commissioned to commence the replication of his botanical sketches and illustrations of ancient Indian monuments. At this time, Napoleon Bonaparte was the only person in Europe with greater fame than Humboldt. Their sole meeting was unsuccessful, with Napoleon responding coldly, possibly viewing Humboldt as a politically suspect foreigner. Despite this, Napoleon granted a pension to Bonpland but later attempted to expel Humboldt from Paris on suspicion of espionage. Paris, despite political changes since Humboldt’s departure, was now the leading center of science, offering exceptional resources and collaborators. Humboldt chose to remain, preferring Paris’s intellectual and social environment over Berlin, which he considered unappealing. He immersed himself in work, organizing his extensive collections and distributing specimens to various institutions. Bonpland kept the most complete set of plant specimens, with other collections sent to major European botanical gardens. Humboldt’s dedication to processing and publishing his scientific findings required several years of intense effort. During their American expedition, Alexander von Humboldt and Aimé Bonpland encountered numerous challenges and hardships, many of which were described in Humboldt’s Voyage aux régions équinoxiales du Nouveau Continent and related works.
Anethole trithione, anetholtrithione, or anetholtrithion (JAN) is a drug used in the treatment of dry mouth. It is listed in the U.S. National Cancer Institute's Dictionary of Cancer Terms as being studied in the treatment of cancer. Anethole trithione is an organosulfur compound, specifically, a dithiole-thione derivative.
== Design and manufacture == The design and manufacture of PMPs involves biomaterial selection, nanoparticle engineering, surface functionalization, and scalable production techniques to mimic the structure, function, and biomechanical properties of native platelets. One such design is a nanohair decorated microsphere made by a research group. These are small particles created from a combination of polystyrene, polyaniline (PANi), and epithelial cell adhesion molecule (EpCAM) antibodies that bind to circulating tumor cells. These spheres are designed to have a 1μm diameter created with the polystyrene molecules where the inner layer is hydrophilic to surround the core. The PANi is used to create nanohairs that simulate the natural aggregation of platelets. These nanohairs are attached to the surface of the polystyrene nanoparticles and range in length from 100 to 800 nm. The EpCAM antibodies are also attached to the nanospheres and are capable of binding to the EpCAM of circulating tumor cells in order to capture and remove them from circulation.
== WADA proscription == In 2015, Radwa Arafa Abd Elsalam, an athlete from Egypt, underwent a doping control where ractopamine was identified in the sample. Elsalam was sanctioned by the Egyptian Anti-Doping Organisation (EGY-NADO) with a two year ineligibility period for non-intentional presence of a prohibited substance, in violation of Article 2.1 of the EGY-NADO rules. While not mentioned by name in the 2015 Prohibited List, ractopamine was determined to — much like clenbuterol, another β2-adrenergic agonist — constitute an Other Anabolic Agent prohibited under S1.2. Elsalam appealed the decision, claiming that ractopamine is used in the meat industry overseas, so she must have inadvertently consumed food contaminated with ractopamine. EGY-NADO accepted her appeal, reduced the sanction to six months, and provided the World Anti-Doping Agency (WADA) with records pertaining to the case. WADA filed an appeal with the Court of Arbitration for Sport (CAS) against EGY-NADO and Elsalam with respect to the appealed decision. WADA asserted ractopamine was "undisputed[ly]" an Other Anabolic Agent, that "[i]t is not sufficient for an athlete merely to make protestations of innocence and suggest that the prohibited substance must have entered her body in inadvertently", and that "her explanations are nothing more than mere speculation".
Sources: en.wikipedia.org
== Biological background == The genetic instructions of every replicating cell in a living organism are contained within its DNA. Throughout the cell's lifetime, this information is transcribed and replicated by cellular mechanisms to produce proteins or to provide instructions for daughter cells during cell division, and the possibility exists that the DNA may be altered during these processes. This is known as a mutation. At the molecular level, there are regulatory systems that correct most — but not all — of these changes to the DNA before it is replicated. One of the possible mutations that occurs is the replacement of a single nucleotide, known as a point mutation. If a point mutation occurs within an expressed region of a gene, an exon, then this will change the codon specifying a particular amino acid in the protein produced by that gene. Despite the redundancy in the genetic code, there is a possibility that this mutation will then change the amino acid that is produced during translation, and as a consequence the structure of the protein will be changed. The functionality of a protein is highly dependent on its structure. Changing a single amino acid in a protein may reduce its ability to carry out this function, or the mutation may even change the function that the protein carries out. Changes like these may severely impact a crucial function in a cell, potentially causing the cell — and in extreme cases, the organism — to die.
1.3 L (1,323 cc) B3-ME, I4 16-valve SOHC, FI, 73–84 PS (54–62 kW; 72–83 hp) / 104–110 N⋅m (77–81 lb⋅ft) (1994–2000) 1.5 L (1,489 cc) Z5-DE, I4 16-valve DOHC, FI, 88–110 PS (65–81 kW; 87–108 hp) / 130–137 N⋅m (96–101 lb⋅ft) (1994–2000) 1.5 L (1,489 cc) Z5-DEL, I4 16-valve DOHC, FI, lean burn, 94 PS (69 kW; 93 hp) / 132 N⋅m (97 lb⋅ft) (1996–1998) 1.5 L (1,498 cc) B5-ZE, I4 16-valve DOHC, FI, 125 PS (92 kW; 123 hp) / 129 N⋅m (95 lb⋅ft) (1994–1996) 1.6 L (1,597 cc) B6D, I4 16-valve DOHC, FI, 115 PS (85 kW; 113 hp) / 140 N⋅m (103 lb⋅ft) (1996–1998) 1.8 L (1,839 cc) BP-ZE, I4 16-valve DOHC, FI, 114–140 PS (84–103 kW; 112–138 hp) / 157–163 N⋅m (116–120 lb⋅ft) (1995–2000) Diesel:
American molecular biologist at the Cold Spring Harbor Laboratory, who proposed the double helical structure of DNA, with Francis Crick. Nobel Prize in Physiology or Medicine (1962). Member Natl. Acad. Sci. USA
Mycosporine-like amino acids (MAAs) are small secondary metabolites produced by organisms that live in environments with high volumes of sunlight, usually marine environments. The exact number of compounds within this class of natural products is yet to be determined, since they have only relatively recently been discovered and novel molecular species are constantly being discovered; however, to date their number is around 30. They are commonly described as "microbial sunscreens" although their function is believed not to be limited to sun protection. MAAs represent high potential in cosmetics, and biotechnological applications. Indeed, their UV-absorbing properties would allow to create products derived from natural photoprotectors, potentially harmless to the environment and efficient against UV damage.
Sources: en.wikipedia.org
Nuclear transitions, including the 'isomeric' variety, occur not only through gamma-ray emission, but also internal conversion where the transition energy instead ejects an electron from the atom, and internal pair production where the transition energy creates an electron-positron pair that are then ejected from the atom. The two processes always compete, with gamma emission normally the most common, but as the proportion converted increases with lower energy and also with forbiddenness, it often becomes important for metastable isomers. In fact, the usual decay of 99m43Tc involves conversion to the spin-7/2 state, then prompt gamma emission to the spin-9/2 ground state; similarly, 180m73Ta could decay through conversion to the spin-2 state, followed by a gamma decay to the ground state. This gamma was looked for in, which assumed that to be the likely decay scheme, and not found. In isotopes whose ground state is unstable, isomers can decay by the same modes rather than going to the ground state. Often both are seen, but rates can differ so much that only one is. Both isomers discussed just above have unstable ground states: 9943Tc undergoes beta decay, though slowly (half-life 211 ky) due to forbiddenness, and the isomer, which is less so, beta-decays over 10,000 times faster (though still a small minority of decays); 18073Ta can fall to either beta decay or electron capture, and quickly (half-life 8.15 h) as it is not forbidden, there the isomer is much more so to either as well as to isomeric transition, explaining its stability.
Since 1901, the Nobel Prize has been awarded to a total of 1026 individuals and organizations as of 2025. In 2025, The United States has the highest number of Nobel laureates in the world, with over 425 Nobel laureates. Around 71% of all Nobel Prizes have been awarded to Americans; around 29% of them are immigrants from other nations. U.S. President Theodore Roosevelt was the first American to win a Nobel Prize of any kind, being awarded the Nobel Peace Prize in 1906 for his role in negotiating peace for the Russo-Japanese War. Albert Michelson was the first American to win a Nobel Prize in any of the sciences, and Sinclair Lewis was the first American to win the Nobel Prize in Literature.
Bully: Brett Height: 5'8 Weight: 164 lb Victim(s): Zack Fighter: Abel Cullum Height: 5'7 Weight: 158 lb Money earned by Bully: $1000 Money earned by victim(s): $9000 Original airing: Friday October 4, 2012.
Sources: en.wikipedia.org
The peptide backbone and its fatty acid side chain are susceptible to degradation at elevated temperatures. Refrigeration slows hydrolysis, oxidation, and aggregation processes. Labeled storage ranges reflect stability data generated under defined conditions.
Mass spectrometry establishes the molecular mass and can detect sequence variants. Reversed-phase chromatography assesses purity and related substances. Peptide mapping after digestion confirms the amino acid sequence itself.
Typical fields include appearance, purity by chromatographic area, mass confirmation, and water or counterion content. Some documents also list residual solvents and microbial limits. The specific fields depend on the supplier and the intended application.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.